Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center

Background Eribulin improves survival in pre-treated HER2-negative advanced breast cancer (ABC). However, limited data exist on co-morbidities and central nervous system (CNS) efficacy. The purpose of this study was to review eribulin's efficacy and safety in everyday clinical practice with special focus on age, body mass index (BMI) and central nervous system (CNS) activity. Methods An observational study was conducted in a series of HER2-negative ABC patients treated from January'14-December'17 outside a clinical trial. Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS), and association of clinical and pathological variables with outcome were evaluated. Results Ninety-five women were treated with at least one cycle of eribulin. Median age was 57 (33-83), and 18% were obese. Median number of prior chemotherapies for ABC was 3 (2-5) and 76% of patients had visceral metastases, including 21% with CNS involvement. Most tumors were estrogen receptor-positive (79%). ORR and stable disease (SD) at 6 months were 26.2 and 37.5%, respectively. Remarkably, relevant CNS efficacy was observed with eribulin: 20% of patients obtained partial response and 25% SD. Treatment was generally well tolerated and manageable, with 29% grade 3 and 10.9% grade 4 toxicities. Median PFS and OS were 4.1 months (CI95% 3.2-4.9) and 11.1 months (CI95% 9.5-14.7), respectively. Triple-negative disease, > 2organs involved and being younger than 70 years old were independent prognosis factors for worse OS in multivariate analysis. Most patients (75%) progressed in pre-existing metastases sites. Conclusion In everyday clinical practice, eribulin's efficacy seems similar to pivotal trials. CNS-efficacy was observed. TNBC, > 2 organs involved and being younger than 70 years old were independent prognosis factors for worse OS. Remarkably, less incidence of grade 4-toxicity compared to previous studies was found

ICO-ICS Praxis para el tratamiento médico del cáncer epitelial de ovario

Tractament mèdic; Càncer epitelial d'ovari; CirurgiaTratamiento médico; Cáncer epitelial de ovario; CirugíaMedical treatment; Ovarian epithelial cancer; SurgeryEl càncer epitelial d'ovari (CEO) és la segona neoplàsia ginecològica més freqüent als països desenvolupats i constitueix la principal causa de mort per càncer ginecològic i la quarta causa de mort per càncer en dones a Europa i als Estats Units. Els objectius d'aquesta guia són -Desenvolupar, difondre, implementar i avaluar resultats de la ICO-ICSPraxi de CEO epitelial. -Disminuir la variabilitat terapèutica entre les pacients tractades als diversos centres d’aquesta institució. -Implementar els resultats de la terapèutica en les pacients amb CEO epitelial tractades d’acord amb les recomanacions d’aquesta guia

ICO-ICS Praxis para el tratamiento médico del cáncer epitelial de ovario

Tractament mèdic; Càncer epitelial d'ovari; CirurgiaTratamiento médico; Cáncer epitelial de ovario; CirugíaMedical treatment; Ovarian epithelial cancer; SurgeryEl càncer epitelial d'ovari (CEO) és la segona neoplàsia ginecològica més freqüent als països desenvolupats i constitueix la principal causa de mort per càncer ginecològic i la quarta causa de mort per càncer en dones a Europa i als Estats Units. Els objectius d'aquesta guia són -Desenvolupar, difondre, implementar i avaluar resultats de la ICO-ICSPraxi de CEO epitelial. -Disminuir la variabilitat terapèutica entre les pacients tractades als diversos centres d’aquesta institució. -Implementar els resultats de la terapèutica en les pacients amb CEO epitelial tractades d’acord amb les recomanacions d’aquesta guia